Topic
8 facts from 2 episodes, in date order. These are what speakers said on the shows, each linked to the moment it was said. They aren't independently verified.
Undated
Walmsley said GSK's consumer division was built through two global joint ventures, first with Novartis's portfolio and then with Pfizer's.
“we went through two massive global joint ventures, firstly with Novartis's portfolio and integrations, frankly, uh, and then with Pfizer's.”
Undated
Kellen Winters is Director of Customer Success and Business Operations for AI at Novartis.
“Today's guest is Kellen Winters, Director of Customer Success and Business Operations for AI at Novartis.”
Undated
Winters says Novartis saw almost a 200% increase within a year in employees wanting to use AI for things like agents.
“we saw almost 200% increase in folks wanting to use AI for things like agents.”
Undated
Novartis ranked seven or eight AI opportunity areas and narrowed them to two where incremental value could be measured over time.
“stack rank the top seven or eight different areas where we saw those opportunities. Really whittle it down to two where that we could really show and measure the incremental value over time.”
Undated
Novartis collected AI ideas by email and messages and set up a monthly quorum meeting to review them.
“We're getting emails, pings from everybody who has these ideas, and we stood up a quorum where we would meet every single month.”
Undated
Winters says Novartis's idea intake process has evolved from a spreadsheet and meetings into an AI agent.
“And now this has kind of transformed into an agent. Because not only again, to your point, is it empowering people to really think in an A I first way”
Undated
Winters says the intake system lets Novartis track incremental value through proof-of-concept phases.
“once we start to work through the P O C phases of this, we're actually able to track that incremental value over time”
Undated
Winters says a mentor at Novartis told her that the company will always be a little behind.
“One of my mentors at Novartis said to me in the most earnest way that we're always gonna be a little bit behind.”
Episodes